Can oral semaglutide (Rybelsus) cause muscle weakness?

Oral Semaglutide and Muscle Weakness

Oral semaglutide (Rybelsus) does not directly cause muscle weakness as a primary pharmacologic effect, but it can lead to loss of muscle mass during weight loss, which may manifest as weakness, particularly in older adults or those with pre-existing muscle conditions.

Evidence from FDA Drug Labeling

The FDA label for Rybelsus does not list muscle weakness as a recognized adverse effect 1. The pharmacodynamic profile shows that semaglutide works through glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying—none of these mechanisms directly impair muscle function 1.

Body Composition Changes During Treatment

Expected Muscle Loss with Weight Reduction

When semaglutide induces weight loss, muscle mass decreases alongside fat mass, though fat loss predominates:

• Oral semaglutide reduces body fat significantly while preserving relative muscle mass: In Japanese patients with type 2 diabetes, 24 weeks of treatment decreased fat mass by 5.6 kg but skeletal muscle by only 1.4 kg, with no significant change in skeletal muscle index, calf circumference, or grip strength 2

• Chinese population data confirms muscle preservation: Fat mass decreased by 15.6% versus only 4.8% muscle mass loss, with maintained grip strength and calf circumference 3

• Network meta-analysis shows semaglutide causes greater fat-free mass loss than placebo: Semaglutide decreased FFM by -1.68 kg (95% CI: -2.84 to -0.52) compared to placebo, which was more than metformin but reflects the substantial overall weight loss 4

Physical Function Remains Intact

Critically, despite measurable muscle volume reduction, functional capacity is typically maintained or improved:

• In people with HIV receiving semaglutide, psoas muscle volume decreased by 9.3%, but chair rise time and gait speed showed nonsignificant improvements, and the prevalence of slow gait speed actually decreased from 63% to 46% 5

• This suggests that the muscle loss is proportional to overall weight reduction and does not translate to functional impairment in most patients 5

High-Risk Populations Requiring Vigilance

Older Adults with Sarcopenia Risk

The most concerning scenario is semaglutide-induced sarcopenia in elderly patients: A 74-year-old man developed progressive fatigue and reduced walking endurance after 8 kg weight loss on semaglutide, with reduced muscle bulk and strength on examination 6. His symptoms improved after dose reduction and implementation of resistance exercise 6.

Key clinical pearl: In older adults (≥65 years), monitor for:

• Progressive fatigue disproportionate to glycemic improvement
• Declining walking speed or endurance
• Difficulty rising from chairs without assistance
• Visible reduction in muscle bulk

Rare but Serious: Rhabdomyolysis

One case report documents rhabdomyolysis with myalgias, weakness, and elevated CK associated with semaglutide: A 47-year-old woman developed symptoms consistent with rhabdomyolysis that resolved with discontinuation and recurred upon rechallenge 7. This appears to be an idiosyncratic reaction rather than a class effect 7.

Monitor for: Unexplained muscle pain, weakness, dark urine, and check CK if suspected.

Paradoxical Benefit in Specific Myopathies

Interestingly, semaglutide reversed chronic myopathy in a patient with hyperkalemic periodic paralysis: A 48-year-old man with permanent muscle weakness from hyperPP regained the ability to rise from a chair and improved his gait speed dramatically after starting semaglutide 8. This suggests GLP-1 agonists may have direct beneficial effects on skeletal muscle independent of weight loss in certain conditions 8.

Clinical Management Algorithm

For patients starting oral semaglutide:

1. Baseline assessment: Document muscle strength (grip strength, chair rise test), gait speed, and functional status—especially in patients ≥65 years

2. Implement concurrent resistance training: This is critical to preserve muscle mass during weight loss. Prescribe 2-3 sessions weekly of progressive resistance exercise

3. Ensure adequate protein intake: Target 1.2-1.6 g/kg ideal body weight daily to minimize muscle catabolism

4. Monitor at 12 and 24 weeks: Reassess functional status, not just weight and HbA1c

5. If weakness develops:

   • Rule out other causes (electrolyte abnormalities, thyroid dysfunction, vitamin deficiencies)
   • Check CK if myalgias present
   • Consider dose reduction (as in the sarcopenia case 6)
   • Intensify resistance training program
   • If severe or progressive, discontinue semaglutide

Guideline Context

The 2025 ADA Standards of Care position GLP-1 receptor agonists as high to very high efficacy agents with cardiovascular and renal benefits 9. The guidelines note GI side effects and other concerns but do not specifically address muscle-related adverse effects 9, likely because functional impairment is uncommon when appropriate lifestyle interventions accompany treatment.

The muscle mass loss with semaglutide is proportional to weight loss and generally does not impair function when patients maintain physical activity and adequate nutrition. The exception is vulnerable older adults with pre-existing sarcopenia, who require closer monitoring and proactive muscle-preserving interventions.